Pediatric Emergencies : Newsletter 9

J.S. Surpure

The University of Oklahoma, Department of Pediatrics, College of Medicine, Oklahoma Children's Memorial Hospital, Oklahoma City Oklahoma, USA.

MEDICATIONS FOR RESPIRATORY VIRUSES

Respiratory tract infections are the single most common reason for outpatient pediatric visits. More than 90% of these infections (excluding otitis media) are caused by viruses, are self-limited, and do not require specific antiviral chemotherapy. However, some viral respiratory infections can be severe or even fatal, particularly those attributable to influenza A and B. Respiratory syncytial virus (RSV) can cause severe or complicated infection in infants younger than 2 months of age and in older infants with cardiopulmonary disease or immunodeficiency. These infants should be considered candidates for antiviral therapy. Epidemiologic observations, chest X-ray interpretation, and physical findings allow the physician to select potentially useful antiviral agents for patients with severe respiratory infection. What medications are available to treat viral infections, and what are the indications for using them? Steels (Pediatr Infect Dis J 1988; 7 : 457) reviewed the spectrum of antiviral agents for respiratory infections.

Amantadine is licensed for prophylaxis and treatment of influenza. Symptoms observed in 10-25% of recipients include insomnia, fatigue, difficulty concentrating, nervousness, and depression. One hundred mg twice daily in adults reduced influenza attack rates by 70-90%. Equally effective was a dosage of 100 mg once daily in teenagers. The dosage in children is 5-8 mg/kg/day divided every 12 hours (maximum 200 mg/day). Protection from symptomatic infection is increased by 10-20% with combined vaccine and chemoprophylaxis compared to either modality used alone. For treatment of documented influenza infection, medication should be started within 48 hours of onset at dosages identical to the prophylaxis dosages and continued for 7 days.

Rimantadine is an analogue of amantadine and will probably soon be licensed for general clinical use. Indications are essentially the same as those for amantadine. Adverse reactions associated with amantadine are uncommon with rimantadine.

Ribavirin is a broad spectrum virustatic agent with activity against RSV, influenza A and B, parainfluenza, and adenovirus. It is presently approved by the Food and Drug Administration in its aerosolized form for the therapy of RSV infections in hospitalized children who do not require assisted ventilation. Although direct fluorescence and enzyme-linked immunosorbent (ELISA) assays for RSV infection are commercially available, these are difficult to establish in the usual community hospital. Aerosolized ribavirin has also been
shown to offer therapeutic benefits in the
treatment of uncomplicated influenza A
and B infection. Studies comparing oral
amantadine or rimantadine to aerosolized
ribavirin for the treatment of influenza A
pneumonia have not been done. Toxicity of
aerosolized ribavirin in infants appears
minimal.

A number of published reports have in-
dicated that interferon given as a nasal
spray reduced the incidence of subsequent
rhinovirus upper respiratory infections.
General application of interferon therapy
has become more available because ad-
vances in genetic engineering allow pro-
duction of large amounts of purified mate-
rial at relatively low cost. Interferon may
have antiviral activity against a broad spec-
trum of pathogens, including rhinovirus,
influenza A and B, parainfluenza, adeno-
virus, and coronavirus. Resistant viral
strains following therapy have not been ob-
served. Systemic toxicity does not occur
except with extremely large doses. Between
12 and 15% of volunteers experienced na-
sal dryness, bleeding ulcerations, and ero-
sion. Interferon has not been effective for
the treatment of established rhinovirus in-
fiction. Furthermore, prophylactic efficacy
data are available only for rhinovirus and
not for other virus infections.

Vitamin C (ascorbic acid) does not
seem to be effective for prevention and
treatment for the common cold. Clinical
trials have also failed to demonstrate any
efficacy of zinc for treatment of rhinovirus
infections. One intriguing approach to
therapy utilizes murine monoclonal anti-
bodies by intranasal administration to
block cellular receptor sites for rhino-
viruses. Transmission of cold viruses com-
monly occurs from colonized hands and
fomites. Such spread can be interrupted by
requiring infected individuals to use hand-
kercloths impregnated with citric acid,
malic acid or other virustatic agents. How-
ever, investigations have not been con-
ducted to establish that treated products do
indeed control transmission of cold viruses.
Acyclovir is probably effective for treating
pulmonary infections caused by herpes
simplex type I or II and varicella zoster.
Ganciclovir, an investigational compound,
ofers promise for the prevention and
treatment of cytomegalovirus disease. Fi-
nally, combination chemotherapy plus im-
munotherapy and other forms of combined
antiviral agents warrant further considera-
tion in the prophylaxis and treatment of vi-
ral respiratory infections.

OPTIONS FOR INITIAL EMPRIC MENINGITIS
THERAPY

Considerable attention has been fo-
cused recently on the alteration of anti-
microbial regimens in an effort to im-
prove outcome from bacterial meningitis in
infants and children. Conventional therapy
with ampicillin and either an aminoglyco-
side or chloramphenicol continues to be
recommended by the American Academy
of Pediatrics. However, the new cephal-
osporins have been used recently for initial
empiric treatment of meningitis because
of their increased activity against the com-
mon meningeal pathogens or because
some of these compounds can be admini-
stered 1-3 times daily (compared with
ampicillin and chloramphenicol which re-
quire 4 doses daily). Is there a regimen of
choice for initial treatmeent? McCracken,
Nelson et al (Pediatr Infect Dis J 1987; 6 :
501)5 reviewed the evidence for efficacy of
the new cephalosporin compounds in the
treatment of pediatric meningitis.

In several recent controlled, prospective
studies, some newer cephalosporins did not sterilize CSF cultures more rapidly nor did they improve case-fatality rates compared with conventional antibiotic regimens in neonates and older children (providing that the pathogens were susceptible to the antibiotic used). However, a potential advantage of the new cephalosporins is the avoidance of the need to monitor serum concentrations of aminoglycosides and chloramphenicol, especially in patients who have underlying abnormalities in renal or hepatic function, respectively.

After comments from several experts, the authors conclude that there is no longer a regimen of choice for initiating treatment of bacterial meningitis. In fact, each of the experts has more than one preferred regimen tailored to specific clinical situations. There was partial consensus on the following points: (1) the reluctance to accept 7-day therapeutic regimens (too short), (2) cefuroxime may not be an ideal choice, (3) third generation cephalosporins seem to be preferred as initial therapy for meningitis in older infants and younger children. The new cephalosporins, therefore, are attractive for reasons of simplicity and safety, but clearly there are cases in which the older regimens are appropriate.

Diagnostic Aid for Elbows

Injuries of the elbow in children are difficult to diagnose accurately, because the multiple ossification centers are primarily cartilaginous and not visible on routine X-rays. Arthrography has been suggested as a means of discerning the injury pattern before complete ossification of the elbow. Is arthrography helpful in diagnosis of these injuries? Yates and Sullivan (J Pediatr Orthop, 1987; 7: 54)³ studied 36 children under 8 years of age with elbow injuries to evaluate the diagnostic accuracy and clinical efficacy of elbow arthrograms. The authors used double-contrast arthrography, with equal volumes of contrast material and air (usually ½-1 ml of each). All arthrograms were obtained within 24 hours of injury with the exception of one child referred for evaluation 10 days following trauma. All arthrographic diagnoses were confirmed by subsequent clinical and radiographic courses.

Many elbow injuries are misdiagnosed by routine X-ray methods and are subsequently managed inappropriately. The most common arthrographic diagnosis in this study was supracondylar fracture, followed by lateral condylar fracture, distal humeral epiphyscal fracture/separation, olecranon fracture, medial epicondylar avulsion with elbow dislocation, contusion, Nursemaid's elbow, and septic elbow. The additional information gained by arthrographic evaluation not only better defined the anatomic lesion, but also favorably influenced subsequent treatment in 7 of the 36 children. The authors conclude that arthrography can be helpful in the skeletally immature patient whose diagnosis is in doubt and is particularly useful in condylar fractures and periarticular fractures in which anatomic alignment cannot be ascertained from plain X-ray. However, arthrography should be needed infrequently overall as long as proper radiographs (including comparison views) are obtained.

Antipyretics for Diagnosis?

Fever is the most common presenting symptom in most pediatric clinics. Many health care providers believe that a fever of benign (usually viral) etiology responds better to antipyretics than a fever caused by
a more serious (bacterial) infection. Is this belief fact or fiction? Weisse et al (Pediatric Infect Dis J 1987; 6 : 1091) studied the effect of acetaminophen on fever in bacterial vs viral infections in 100 children (ages 9 days to 17 years) with rectal or oral temperature of 102°F (38.9°C) or greater. Study patients were given 15 mg/kg (maximum 650 mg) acetaminophen, and their temperatures were rechecked 1 hour later.

Previous studies have indicated that the risk of bacteremia increases with certain threshold elevations of white blood cell count, erythrocyte sedimentation rate, and temperature. Results have been ambiguous concerning the use of subjective analysis of a patient's "toxicity" to predict bacteremia. These authors agree with previous studies which showed that the risk of bacteremia increases with increased white blood cell count. Furthermore, they found that the fever response to acetaminophen was a poor discriminator between bacterial and viral infections. They suggest that additional study including a more prolonged period of patient temperature measurements might be helpful to more fully understand this clinical question.

SCORING ASTHMA

Asthma is the most common lung disease in children beyond infancy. A number of clinical scoring systems have been devised that are intended to help assess the severity of the asthma episode. One such scoring system is the clinical asthma score (CAS) developed by Wood and co-workers in 1972. The use of CAS has not been validated by adequate clinical trials. Does the CAS have prognostic value? Baker (AJDC, 1988; 142 : 183) studied 210 asthma patients to evaluate the usefulness of the CAS in determining outcome in childhood asthmatics. All patients received standard treatment, consisting of beta-adrenergic agents and theophylline compounds. The CAS is the summation of values assigned to 5 different clinical characteristics, which include cyanosis, inspiratory breath sounds, accessory muscle use, expiratory wheezing, and cerebral function. The decision to admit or discharge a patient was based on the treating physician's clinical assessment. Follow-up information was gathered by telephone on each child 10 days after emergency department disposition.

The author found that the pretreatment CAS was not useful for the early identification of children requiring prolonged inpatient asthma management. Although the CAS might be reflective of the severity of illness at the time of assessment, it is of little use in predicting the direction of illness as reflected either by the length of hospitalization or the continuation of clinically significant symptoms at home. These data indicate that the CAS alone is not a reliable indicator of severity of acute asthma of childhood as judged by subsequent disability.

REFERENCES

1. Weisse ME, Miller, G, Brien, JH. Fever response to acetaminophen in viral vs bacterial infections. Pediatric Infect Dis J 1987; 6 : 1091-1094
2. Baker MD. Pitfalls in the use of clinical asthma scoring AJDC 1988; 142 : 183-185.
3. Yates C, Sullivan JA. Arthrographic diagnosis of elbow injuries in children Journal of Pediatric Orthopedics 1987; 7 : 54-60
4. Steele RW. Antiviral agents for respiratory infections. Pediatric Infect Dis J 1988; 7 : 437-440
5. McCracken GH, Nelson JD, Kaplan SL et al. Consensus report : Antimicrobial therapy for bacterial meningitis in infants and children Pediatric Infect Dis J 1987; 6 : 501-505.